ATOS · XBRL financial data
Atossa Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ATOS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 6,608 | 9,210 | 15,083 | 17,334 | 14,117 | 21,185 |
| General and administrative | 7,999 | 11,311 | 12,608 | 14,043 | 13,504 | 15,956 |
| Total operating expenses | 14,607 | 20,521 | 27,691 | 31,377 | 27,621 | 37,141 |
| Operating income (loss) | (14,607) | (20,521) | (27,691) | (31,377) | (27,621) | (37,141) |
| Interest income | — | 6 | 877 | 4,343 | 4,050 | 2,377 |
| Other income (expense) | 51 | (85) | (146) | (70) | (223) | (6) |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (17,828) | (20,606) | (26,960) | (30,094) | (25,504) | (34,770) |
| Earnings per share, basic‡ USD per share | — | (2.69) | (3.13) | (3.58) | (2.99) | (60.30) |
| Earnings per share, diluted‡ USD per share | — | — | (3.13) | (3.58) | (2.99) | (60.30) |
| Weighted average shares, basic‡ thousands of shares | — | 7,836 | 8,484 | 8,447 | 8,433 | 577 |
| Weighted average shares, diluted‡ thousands of shares | — | — | 8,484 | 8,447 | 8,433 | 577 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (February 2026); filings made before it reported them unadjusted.
- † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ATOS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 39,554 | 136,377 | 110,890 | 88,460 | 71,084 | 41,299 |
| Prepaid and other current assets | — | — | 1,207 | 2,162 | 1,165 | 1,128 |
| Total current assets | 42,770 | 141,240 | 118,197 | 92,219 | 74,457 | 45,618 |
| Property and equipment, net | 21 | 20 | — | — | — | — |
| Right-of-use asset | 18 | 0 | 0 | — | — | — |
| Total assets | 42,839 | 141,262 | 123,532 | 96,252 | 76,444 | 47,608 |
| Accounts payable | 1,589 | 1,717 | 2,965 | 806 | 679 | 4,293 |
| Accrued liabilities | 93 | 204 | 1,059 | 973 | 919 | 1,307 |
| Total current liabilities | 15,672 | 3,126 | 5,568 | 5,236 | 4,967 | 8,255 |
| Total liabilities | 15,672 | 3,126 | 5,568 | 5,236 | 4,967 | 8,255 |
| Accumulated deficit | (111,899) | (129,234) | (156,194) | (186,288) | (211,792) | (246,562) |
| Total stockholders' equity | 27,168 | 138,136 | 117,964 | 91,016 | 71,477 | 39,353 |
| Total liabilities and equity | 42,839 | 141,262 | 123,532 | 96,252 | 76,444 | 47,608 |
| Common shares outstanding (cover page)‡ thousands of shares | 8,095 | 8,484 | 8,484 | 8,395 | 8,654 | 577 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (February 2026); filings made before it reported them unadjusted.
- † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ATOS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (17,828) | (20,606) | (26,960) | (30,094) | (25,504) | (34,770) |
| Stock-based compensation | — | — | 6,788 | 4,621 | 2,292 | 2,646 |
| Depreciation and amortization | 47 | 23 | 8 | — | — | — |
| Net cash from operating activities | (11,570) | (16,472) | (20,760) | (20,941) | (21,030) | (29,762) |
| Purchases of property and equipment | 9 | 9 | 27 | 14 | 19 | 23 |
| Net cash from investing activities | (9) | (9) | (4,727) | (14) | (19) | (23) |
| Proceeds from issuing equity | — | 113,486 | — | — | — | — |
| Share repurchases | — | — | 0 | 1,475 | 0 | — |
| Net cash from financing activities | 38,552 | 113,304 | 0 | (1,475) | 3,673 | 0 |
| Net change in cash | 26,973 | 96,823 | (25,487) | (22,430) | (17,376) | (29,785) |
- † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Atossa Therapeutics | 26,094 | not reported | (9,644)* | 10.0M | 2.7 quarters | 10-QJun 30, 2026 |
| Fennec Pharmaceuticals | 41,249 | 17,874 | 50* | 35.1M | — | 10-QJun 30, 2026 |
| Cartesian Therapeutics | 147,606 | 0 | (21,082)* | 30.3M | 7.0 quarters | 10-QJun 30, 2026 |
| Galectin Therapeutics | 13,269 | not reported | (2,439)* | 100.8M | 5.4 quarters | 10-QJun 30, 2026 |
| Achieve Life Sciences | 47,958 | not reported | (10,777)* | 102.9M | 17.4 quarters | 10-QJun 30, 2026 |
| Enanta Pharmaceuticals | 33,419 | 14,359 | (9,972)* | 29.1M | 19.0 quarters | 10-QJun 30, 2026 |
| TuHURA Biosciences | 996 | not reported | (8,634)* | 63.7M | 0.1 quarters | 10-QJun 30, 2026 |
| Vaxart | 50,929 | 27,185 | 2,778* | 242.8M | — | 10-QJun 30, 2026 |
| Ironwood Pharmaceuticals | 79,127 | 113,041 | 58,276* | 165.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.